Company attributes
Other attributes
Lineage is a clinical-stage biotechnology company developing novel cell therapies. It is a company that engages in the development cell therapies for unmet medical needs. It focuses on the development of therapies for degenerative retinal diseases, neurological conditions that are associated with demyelination and aiding the body in the detection and fight against cancer.
Lineage’s programs are based on the its proprietary cell-based therapy platform and associated development and manufacturing capabilities. It uses its platform to develop and manufacture specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials.
Lineage is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. Lineage has three allogeneic cell therapy programs which are: OpRegen, OPC1 and VAC2. Its OpRegen is a retinal pigment epithelium cell replacement therapy that is being developed for treating advanced dry age-related macular degeneration with geographic atrophy, Its OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries, while its VAC2 is a cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.
